Group B meningococcal vaccine science and policy.
Capsular group B Neisseria meningitidis is one of the leading causes of death in developed countries. A new vaccine (4CMenB) has recently been developed which was found to have an acceptable safety profile in clinical studies and to be immunogenic. This review examines the evidence supporting the licensure of the 4CMenB vaccine and discusses recommendations for its use.
Oxford Vaccine Group, Department of Paediatrics, University of Oxford, United Kingdom; NIHR Oxford Biomedical Research Centre, Level 2, Children's Hospital, Oxford OX3 9DU, United Kingdom. Electronic address: simon.drysdale@paediatrics.ox.ac.uk.
Simon B
SB
Drysdale
Oxford Vaccine Group, Department of Paediatrics, University of Oxford, United Kingdom; NIHR Oxford Biomedical Research Centre, Level 2, Children's Hospital, Oxford OX3 9DU, United Kingdom. Electronic address: andrew.pollard@paediatrics.ox.ac.uk.
Andrew J
AJ
Pollard
D000293:Adolescent; D000328:Adult; D002648:Child; D002675:Child, Preschool; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D008589:Meningococcal Infections / Q000453:epidemiology / Q000382:microbiology / Q000517:prevention & control; D022401:Meningococcal Vaccines / Q000008:administration & dosage / Q000009:adverse effects / Q000276:immunology; D008875:Middle Aged; D038541:Neisseria meningitidis, Serogroup B / Q000276:immunology*; D055815:Young Adult
C570015:4CMenB vaccine; D022401:Meningococcal Vaccines
Capsular group B Neisseria meningitidis; Capsular group C Neisseria meningitidis; Children; Immunogenicity; Infant; Reactogenicity; Vaccine